Akorn, Inc.
https://www.akorn.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akorn, Inc.
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs
Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.
Jazz’s CNS Pipeline Demonstrates Transformation
With a first-in-class cannabis-derived treatment for epilepsy, a market-leading treatment for sleep disorders and now a foray into movement disorders, Jazz’s CNS pipeline is strong.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Merus Gains Momentum Ahead Of Keytruda Combination Results
Results in head and neck cancer for its lead bispecific antibody are expected at ASCO, with signs the FDA could accept an accelerated approval application based only on overall response rate data.
Company Information
- Industry
- Distributors
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Hi-Tech Pharmacal
- Oak Pharmaceuticals, Inc., VersaPharm
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice